SciSure is the result of a bold, deliberate merger between two established names in digital lab technology: eLabNext, long respected for its ELN and LIMS capabilities, and SciShield, a trusted leader in EHS, compliance and lab safety. By combining our offerings, we have become the first Scientific Management Platform (SMP): a true home base for the modern lab. SciSure unites the needs of Scientists, EHS, and LabOps professionals in one connected solution, delivering a seamless experience for safe, efficient, and reproducible scientific advancement. Together, we’re shaping the future of lab digitalization—one platform, every workflow. | x
Sciomics
Protein profiling plays an essential part in today’s biomedical research, striving to improve patients’ quality of life by using molecular signatures for diagnosis and treatment guidance. At Sciomics, we believe that our explorative proteomic and post-translational modification profiling platform enables true progress in precision medicine. Therefore, our internal development pipeline of innovative biomarker signatures for precision medicine is based on this powerful platform. | Protein profiling plays a crucial role in the advancement of biomedical research, enabling us to improve patients’ quality of life by utilizing molecular signatures for accurate diagnosis and treatment. At Sciomics, our passion for advanced protein profiling is driving the future of Precision Medicine. We are continually expanding our biomarker signature pipeline to address a wide range of clinical indications and to advance Precision Diagnostics. Our cutting-edge services enable scientists worldwide to unravel the complexities of disease, uncover modes of action and identify promising protein biomarker candidates. Our service portfolio is anchored in our state-of-the-art scioDiscover microarray platform for protein and post-translational modification profiling. We are proud to support a wide range of research, from basic scientific discovery to breakthrough pharmaceutical initiatives (R&D). scioDiscover is a high-content, high-throughput system that provides a fast and cost-effective solution to your research needs. Its results are seamlessly translated into validation and clinical assays, enabling breakthrough biomarker discovery and preclinical drug development. | Sciomics has a robust immuno-proteomics platform for the development of protein biomarker panels as well as for the support of pre-clinical programs. On this basis we have established our own internal protein biomarker development pipeline and are offering CRO services for our customers in pharma and biotech. Currently, we are building a new venture bridging the gap between biomarker discovery, verification, and the introduction of our biomarker panels into the IVD market. The most advanced project focuses on scioAKI – a four-protein biomarker panel for an early and precise diagnosis of Acute Kidney Injury (AKI, for more details see asset scioAKI). Please get in touch if you are interested in partnering with us or investing in this endeavor. Our internal biomarker development pipeline, with the scioAKI project being our main program, is based on the scioDiscover platform. scioDiscover enables a robust combination of our proteomics data with AI-approaches for the definition of high-performance biomarker panels, both regarding sensitivity and specificity. As the platform is completely immuno-based, findings can be easily transferred to ELISA or similar tools for clinical routine use. In addition to our internal biomarker development pipeline, we offer CRO services based on our scioDiscover protein profiling platform and are welcoming R&D collaborations as well. Main applications are – the discovery and validation of novel biomarkers, – drug target screening, – the characterization of disease models, – the analysis of pathway activity as well as – mode-of-action studies. One of the key advantages in collaborating with us is our team of scientific experts that takes pride in custom-tailoring every project and consulting as well as supporting clients throughout the project. Our full-service ranges from discussing experimental designs to in-depth data analysis and yields a comprehensive study report. Fast and cost-efficient, Sciomics’ powerful high-content, high-throughput antibody array platform delivers reliable results that can be easily translated into validation or clinical assays. Thereby, we are a strong partner in generating value and opening new avenues for biomarker discovery, as well as target discovery and verification as well as preclinical drug development programs.
Scientific Climate Systems
Scientific Climate Systems specializes in the design/build of -40C dew point Dry Rooms for Lithium-Ion Battery Research and Production facilities with sizes ranging from 500 sq. ft. to over 100,000 sq. ft. We provide a Sole Source Responsibility including the mechanical design, construction, installation, adherence to schedule, and a full parts/labor & expenses warranty of our scope of the project specifications. SCS has over 50 years’ experience and we are the largest Dry Room design/build firm in the USA with over 450 Dry Room facilities in North America and abroad. We utilize Professional Engineers and have specialty Project Engineers in all key areas of the design/build process that provides our customers the technical expertise to back our commitment to your facility. Please visit our new website: dryrooms.com
Scienta Lab
Scienta is a techbio company founded in 2021, dedicated to transforming drug development in immunology and inflammation. By combining proprietary disease-specific data assets with next-generation foundation model AI, Scienta bridges the translational gap that has long made I&I drug development among the most costly and failure-prone in the pharmaceutical industry. Despite decades of research and significant investment, the majority of immunology drug candidates still fail in clinical trials, largely due to poor translation from animal models to human patients. Phase II failure rates in I&I remain stubbornly high, driven by an inability to reliably predict which patients will respond to a given therapy before a costly trial begins. Scienta was built to address this challenge at its root. At the core of Scienta’s platform is EVA, the first cross-species, multimodal foundation model dedicated exclusively to immunology and inflammation. EVA learns from ImmunAtlas, Scienta’s proprietary curated database aggregating over 600,000 patient and biosample profiles across more than 30 immune-mediated diseases, integrating clinical, transcriptomic, histological, and proteomic data from 70+ tissues and more than 3 billion biological data points. EVA operates across the full drug development pipeline. At the discovery stage, it enables zero-shot target efficacy and gene function prediction to identify and prioritize the most promising therapeutic mechanisms. In preclinical development, it models cross-species and cross-disease molecular perturbations to anticipate how a drug candidate will impact immune networks in humans, going beyond what animal models alone can reveal. At the clinical stage, it supports patient stratification, treatment response prediction, and disease activity forecasting to identify the right patients for the right therapies before trials begin. In independent benchmarking across 39 immune-specific tasks spanning the drug development pipeline, EVA achieved state-of-the-art results, outperforming both generalist biological foundation models and conventional baselines. These results have been validated through peer-reviewed publications and presentations at leading biomedical and AI conferences. Scienta’s technology has been validated in concrete biopharma partnerships, with applications spanning dermatology, gastroenterology, rheumatology and neurology. Unlike generalist AI platforms or single-cell-focused tools, Scienta combines two capabilities rarely found together: high translational capability bridging preclinical to clinical development, and disease-specific explainability. Models are built to be interrogated, providing mechanistic interpretability that helps scientists understand why a prediction is made. This positions Scienta uniquely at the intersection of molecular precision and systemic, patient-level modeling. Scienta was co-founded by Camille Bouget (CEO, PharmD, previous experience across Sanofi, Sandoz, and Galapagos), Vincent Bouget (CSO, CentraleSupélec / MSc Biomedical Sciences), and Julien Duquesne (CTO, CentraleSupélec / MSc MVA, ENS Paris-Saclay). The company has raised 6.5 million euros in total funding, including support from the European Innovation Council’s EIC Accelerator, the EU’s flagship program for breakthrough deep-tech innovations.
ScienceTrack
ScienceTrack is a Czech startup on a mission to modernize laboratory animal research with intuitive, data-driven software. From colony management to resource scheduling, our solutions streamline daily workflows, improve compliance, and support better science. Our flagship products include ZETA, a powerful animal colony management platform, and ReservAnt, a flexible tool for booking equipment, spaces, and personnel in research facilities. With user-centered design and seamless integration, ScienceTrack empowers labs to focus more on discovery and less on administration. Visit our booth to experience a live demo and learn how ScienceTrack is shaping the future of animal facility operations.
Schunk Sonosystems NA
Schunk Sonosystems is the world’s leading specialist in the field of ultrasonic metal welding. Worldwide, our 300 employees develop and produce our innovative ultrasonic welding equipment – and are always close to our customers. Apart from our headquarters in Wettenberg (Germany) together with our subsidiary Schunk Sonosystems North America, we have, locations in Boston (USA), Taicang (Jiangsu Province, China) and Kenitra (Morocco). Furthermore, about 30 agencies represent us worldwide. Ultrasonic welding is a future-oriented process that joins metals using ultrasound. In addition to copper and aluminum joints, metal-glass joints are also possible. The materials are placed on top of each other and moved against each other under low pressure and high-frequency mechanical vibrations. In this way, a permanent, strong and metallurgically pure joining with excellent physical properties is created in a fraction of a second. | Schunk Sonosystems – the world’s leading specialists for ultrasonic battery and metal welding
Schrödinger
Schrödinger is transforming molecular discovery through a physics-based computational platform that enables the rapid identification of highly optimized molecules for drug development and materials science. With over 30 years of R&D investment, our software is the industry standard—licensed by biotech, pharmaceutical, and industrial leaders, as well as academic institutions globally. Beyond software licensing, Schrödinger leverages its technology to advance a diverse portfolio of collaborative and proprietary drug discovery programs. By integrating predictive modeling with high-performance computing, we are accelerating the path to life-changing therapies and materials. | Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for materials design and drug development. Schrödinger’s software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, pharmaceutical and industrial companies, and academic institutions around the world. Schrödinger also leverages the platform to advance a portfolio of collaborative and proprietary programs. Founded in 1990, Schrödinger has approximately 800 employees operating from 15 locations globally. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com. | Schrödinger is transforming the way materials are discovered. Schrödinger has pioneered a physics-based software platform that enables the discovery of novel materials more rapidly and at lower cost compared to traditional methods. The software platform is used by companies from organic electronics to consumer packaged goods, academic institutions, and government laboratories around the world. The platform has helped researchers in the food and beverage industry accelerate the design and development of sustainable food products.
Schrodinger Inc.
Schrödinger is transforming the way materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Founded in 1990, Schrödinger has over 850 employees and is engaged with customers and collaborators in more than 70 countries. To learn more, visit www.schrodinger.com, follow us on LinkedIn and Instagram, or visit our blog, Extrapolations.com.
SCHOTT Pharma
Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 16 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on the Frankfurt Stock Exchange as part of the MDAX. It is part of SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment and has the strategic goal of becoming climate-neutral by 2030. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com Contact us now: pharma@schott.com Data protection: https://www.schott-pharma.com/en/legal-social
Schold Manufacturing
Engineered for battery material mixing and particle reduction, Schold and EMI Mills deliver industrial dispersers, mixers, and media mills for precision, consistency, and scalability. Our solutions include high-speed/high-shear dispersers, vacuum mixers, inline dispersers, rotor-stator mixers, and more, along with complete mixing systems for electrode slurry production, conductive additives, coatings, and specialty chemistries. For particle size reduction and uniform dispersion, EMI media/bead mills for both laboratory/R&D and large-scale production. All equipment is engineered and manufactured in the USA, serving battery innovators and manufacturers worldwide. Contact our team to discuss your process challenges and request a tailored solution for your next project.